Inhibition of adult T-cell leukemia cell proliferation by polymerized proanthocyanidin from blueberry leaves through JAK proteolysis.
ATL
HSP90
JAK/STAT
blueberry leaf
proanthocyanidin
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
revised:
27
12
2021
received:
06
08
2021
accepted:
19
01
2022
pubmed:
1
2
2022
medline:
12
4
2022
entrez:
31
1
2022
Statut:
ppublish
Résumé
We have previously reported that the proanthocyanidin (PAC) fraction of blueberry leaf extract (BB-PAC) inhibits the proliferation of HTLV-1-infected adult T-cell leukemia (ATL) by inducing apoptosis. In the present study, we further analyzed the structure of BB-PAC and elucidated the molecular mechanism underlying the inhibitory function of HTLV-1-infected and ATL cells. After hot water extraction with fractionation with methanol-acetone, BB-PAC was found to be concentrated in fractions 4 to 7 (Fr7). The strongest inhibition of ATL cell growth was observed with Fr7, which contained the highest BB-PAC polymerization degree of 14. The basic structure of BB-PAC is mainly B-type bonds, with A-type bonds (7.1%) and cinchonain I units as the terminal unit (6.1%). The molecular mechanism of cytotoxicity observed around Fr7 against ATL cells was the degradation of JAK1 to 3 and the dephosphorylation of STAT3/5, which occurs by proteasome-dependent proteolysis, confirming that PAC directly binds to heat shock protein 90 (HSP90). JAK degradation was caused by proteasome-dependent proteolysis, and we identified the direct binding of PAC to HSP90. In addition, the binding of cochaperone ATPase homolog 1 (AHA1) to HSP90, which is required for activation of the cofactor HSP90, was inhibited by BB-PAC treatment. Therefore, BB-PAC inhibited the formation of the HSP90/AHA1 complex and promoted the degradation of JAK protein due to HSP90 dysfunction. These results suggest that the highly polymerized PAC component from blueberry leaves has great potential as a preventive and therapeutic agent against HTLV-1-infected and ATL cells.
Identifiants
pubmed: 35100463
doi: 10.1111/cas.15277
pmc: PMC8990289
doi:
Substances chimiques
HSP90 Heat-Shock Proteins
0
Proanthocyanidins
0
proanthocyanidin
18206-61-6
Proteasome Endopeptidase Complex
EC 3.4.25.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1406-1416Subventions
Organisme : the Shinnihon Foundation of Advanced Medical Treatment Research
Organisme : the Takeda Science Foundation
Organisme : the Japan Society for the Promotion of Science
ID : Grant-in-Aid for Scientific Research (B) 17H03581
Organisme : the Japan Society for the Promotion of Science
ID : Scientific Research (C) 18K07238
Organisme : the Japan Society for the Promotion of Science
ID : Scientific Research (C) 21K07128
Organisme : Shinnihon Foundation of Advanced Medical Treatment Research
Organisme : Takeda Science Foundation
Organisme : Japan Society for the Promotion of Science
ID : 17H03581
Organisme : Japan Society for the Promotion of Science
ID : 18K07238
Organisme : Japan Society for the Promotion of Science
ID : 21K07128
Informations de copyright
© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
J Biol Chem. 2009 Aug 7;284(32):21165-76
pubmed: 19531480
Sci Rep. 2015 Aug 13;5:12841
pubmed: 26269411
Nat Med. 2011 Jun 19;17(7):845-53
pubmed: 21685897
Science. 1995 Jul 7;269(5220):79-81
pubmed: 7604283
J Clin Invest. 1995 Sep;96(3):1548-55
pubmed: 7657825
Molecules. 2020 Dec 16;25(24):
pubmed: 33339407
Antivir Ther. 2009;14(4):533-42
pubmed: 19578238
Cell. 2006 Nov 17;127(4):803-15
pubmed: 17110338
Cancer Sci. 2021 Jan;112(1):22-30
pubmed: 33128318
Blood. 2011 Feb 10;117(6):1938-46
pubmed: 21106989
Biochim Biophys Acta Mol Basis Dis. 2019 Oct 1;1865(10):2633-2646
pubmed: 31295529
Proc Natl Acad Sci U S A. 2015 Oct 6;112(40):12480-5
pubmed: 26396258
J Clin Invest. 2010 Oct;120(10):3578-93
pubmed: 20852385
Cancer Sci. 2022 Apr;113(4):1406-1416
pubmed: 35100463
Nat Commun. 2014 Feb 26;5:3393
pubmed: 24569712
Biomed Pharmacother. 2019 Aug;116:108999
pubmed: 31146109
Toxicol Res. 2017 Oct;33(4):273-282
pubmed: 29071011
J Gen Virol. 1987 Feb;68 ( Pt 2):499-506
pubmed: 3029287
Cancer Res. 2008 Feb 15;68(4):1188-97
pubmed: 18281495
Biochem Biophys Res Commun. 2017 Mar 25;485(1):144-151
pubmed: 28189691
Biochim Biophys Acta Mol Cell Res. 2020 Feb;1867(2):118615
pubmed: 31765670
PLoS One. 2012;7(2):e31067
pubmed: 22348037
Nutr Cancer. 2014;66(4):736-46
pubmed: 24191894
Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13897-902
pubmed: 9391124
Food Chem Toxicol. 2017 Nov;109(Pt 1):534-543
pubmed: 28974439
PLoS One. 2015 May 27;10(5):e0128103
pubmed: 26018525
Signal Transduct Target Ther. 2021 Jan 20;6(1):25
pubmed: 33468990
Oncogenesis. 2017 Apr 3;6(4):e311
pubmed: 28368390
Biomed Res Int. 2018 Mar 12;2018:8584136
pubmed: 29750172
J Immunol. 2006 May 15;176(10):5797-804
pubmed: 16670285
Nat Rev Cancer. 2010 Aug;10(8):537-49
pubmed: 20651736
Cell Rep. 2015 Jun 9;11(9):1458-73
pubmed: 26027934
Carcinogenesis. 2008 Mar;29(3):585-93
pubmed: 17827407
Blood. 2015 Nov 26;126(22):2479-83
pubmed: 26443624
Clin Cancer Res. 2011 Dec 1;17(23):7347-58
pubmed: 21976548
Front Microbiol. 2020 May 29;11:1124
pubmed: 32547527